Cytori Therapeutics Inc

Find Ratings Reports
CYTX : NASDAQ : Health Care
$0.39 | %
Today's Range: 0.3705 - 0.4299
Avg. Daily Volume: 850400.0
09/22/17 - 4:00 PM ET

Financial Analysis


CYTORI THERAPEUTICS INC's gross profit margin for the second quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. CYTORI THERAPEUTICS INC has weak liquidity. Currently, the Quick Ratio is 0.78 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 40.01% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)1.52.83
EBITDA ($mil)-4.97-5.94
EBIT ($mil)-5.58-6.22
Net Income ($mil)-6.05-6.4


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)9.4620.04
Total Assets ($mil)32.4842.68
Total Debt ($mil)14.5217.16
Equity ($mil)11.2318.72


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin60.232.67
EBITDA Margin-331.4-210.3
Operating Margin-372.07-220.32
Sales Turnover0.270.27
Return on Assets-73.58-30.4
Return on Equity-212.78-69.32
Debt Q2 FY17 Q2 FY16
Current Ratio1.182.65
Debt/Capital0.560.48
Interest Expense0.540.65
Interest Coverage-10.37-9.65


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)33.3320.49
Div / share0.00.0
EPS-0.19-0.43
Book value / share0.340.91
Institutional Own % n/a n/a
Avg Daily Volume854581.0855458.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.22 indicates a significant discount versus the S&P 500 average of 3.11 and a significant discount versus the industry average of 12.06. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, CYTORI THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CYTX NM Peers 39.29   CYTX NM Peers 27.33

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CYTX's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CYTX's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CYTX NA Peers 25.51   CYTX NA Peers 0.49

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CYTX 1.22 Peers 12.06   CYTX 0.98 Peers 9.89

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CYTX is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, CYTX is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CYTX 1.56 Peers 99.07   CYTX -24.58 Peers 241.27

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CYTX is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

CYTX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades